Working… Menu

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) (CLARITY-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02580448
Recruitment Status : Completed
First Posted : October 20, 2015
Last Update Posted : February 1, 2019
Information provided by (Responsible Party):
Innocrin Pharmaceutical

Brief Summary:
The goal of this clinical study is to determine the safety, pharmacokinetics, pharmacodynamics and efficacy and activity of seviteronel, a lyase-selective inhibitor of CYP17, in patients with advanced breast cancer.

Condition or disease Intervention/treatment Phase
Cancer of the Breast Breast Cancer Advanced Breast Cancer Metastatic Breast Cancer Male Breast Cancer Triple Negative Breast Cancer ER+ Breast Cancer Drug: Seviteronel Phase 1 Phase 2

Detailed Description:

This is an open-label, Phase 1/2 study of seviteronel in subjects with TNBC or ER +/HER2 normal unresectable locally advanced breast cancer. Only women will be enrolled in Phase 1 and both men and women enrolled into their respective cohorts in Phase 2. There will be a dose confirmation Phase 1 portion of the study to establish the recommended Phase 2 dose (RP2D) for women with breast cancer using a non-stratified, combined cohort of women with TNBC or ER+ BC. Cohort expansion will occur in Phase 2 at the RP2D confirmed/established in Phase 1 using separate TNBC and ER+ cohorts. The Phase 2 portion of the study is divided into three parallel cohorts:

Cohort 1: Female TNBC Subjects Cohort 2: Female ER+ Subjects Cohort 3: Male ER+ BC or TNBC Subjects

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 175 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
Actual Study Start Date : August 2015
Actual Primary Completion Date : January 2019
Actual Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Female Triple Negative Breast Cancer Patients
TNBC Patients - Enrollment is complete in this cohort
Drug: Seviteronel
Seviteronel given daily with evening meal in 28 day cycles

Experimental: Female Estrogen Receptor (+) Breast Cancer Patients
Female ER(+) BC Patients - Enrollment is complete in this cohort
Drug: Seviteronel
Seviteronel given daily with evening meal in 28 day cycles

Experimental: Male Breast Cancer Patients
Locally advanced or metastatic males with BC
Drug: Seviteronel
Seviteronel given daily with evening meal in 28 day cycles

Primary Outcome Measures :
  1. Estimate efficacy of seviteronel as measured by clinical benefit rate at 16 weeks (CBR16) for female subjects with TNBC. [ Time Frame: Duration of Study ]
  2. Estimate efficacy of seviteronel as measured by clinical benefit rate at 24 weeks (CBR24) for female subjects with ER+ BC. [ Time Frame: Duration of Study ]
  3. Estimate efficacy of seviteronel as measured by CBR16 for all male BC subjects. [ Time Frame: Duration of Study ]

Secondary Outcome Measures :
  1. Describe the pharmacokinetics of seviteronel [ Time Frame: At least monthly over the first eight 28-day cycles ]
    Area under the curve concentration verses time curve and Peak Plasma Concentration

  2. Estimate efficacy of seviteronel as measured by the overall response rate (ORR) based on RECIST 1.1 [ Time Frame: At least monthly over the first eight 28-day cycles ]
  3. Estimate efficacy of seviteronel as measured by progression-free survival (PFS) [ Time Frame: At least monthly over the first eight 28-day cycles ]
  4. Describe the safety profile of seviteronel [ Time Frame: Duration of the study ]
  5. Compare the safety profile of seviteronel with or without concurrent glucocorticoid administration [ Time Frame: Duration of the study ]
  6. Compare the CBR16 with or without concurrent glucocorticoid administration for female subjects with TNBC [ Time Frame: Duration of the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Each subject eligible to participate in this study must meet or have all the following criteria:

  1. Is 18 years of age or older.
  2. Can provide written informed consent or have their legal representatives provide written informed consent
  3. Have documented histological or cytological evidence of invasive cancer of the breast, defined by one of the following:

    • ER+ breast cancer, defined as positive if ≥ 1% by IHC and HER2 normal, defined as IHC 0-1+ or IHC 2+(and FISH<2), or FISH < 2.0
    • TNBC, defined as ER-/PgR- if 0 % by IHC and HER2 normal, defined as IHC 0-1+ or IHC 2+(and FISH<2), or FISH < 2.0
  4. ECOG PS of 0 or 1 for Females, 0, 1, or 2 for Males.
  5. Undergoing or willing to undergo gonadal suppression:

    • Female subjects with ER+/HER2 normal tumors must be post-menopausal defined by local practice. Ovarian suppression with a LHRH analogue to achieve cessation of regular menses is allowed on study
    • Male subjects must be undergoing or willing to undergo gonadal suppression whilst on study drug and continue with the LHRH analogue for the duration of the study
  6. Subjects must have adequate hematopoietic function as evidenced by:

    • WBC ≥ 3,000/μl
    • ANC ≥ 1,500/μl
    • Platelet count ≥ 100,000/μl
    • HGB ≥ 9 g/dl and not transfusion dependent
  7. Adequate liver function, including all the following:

    • Total serum bilirubin ≤2.0 x ULN unless the subject has documented Gilbert syndrome;
    • Aspartate and alanine aminotransferase (AST & ALT) ≤3.0 x ULN or ≤5.0 x ULN if subject has liver metastasis;
    • Alkaline phosphatase ≤3.0 x ULN or ≤5 x ULN in case of bone metastasis and/or hepatic metastasis
  8. Subjects must have adequate renal function as evidenced by a serum creatinine of ≤ 2.0 mg/dl.
  9. Potassium (K+) ≥3.5 mEq/L
  10. Women of child-bearing potential must have a negative serum or urine pregnancy test within 72 hours of C1D1.
  11. Women of child-bearing potential and male subjects with a female partner of childbearing potential must use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at Screening and continuing throughout the study period and for 3 months after final study drug administration i. Two acceptable forms of birth control include:

1. Condom (barrier method of contraception), and 2. One of the following:

  1. Oral, injected or implanted hormonal contraception
  2. Placement of an intrauterine device (IUD) or intrauterine system (ISU)
  3. Additional barrier methods of contraception: Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
  4. Vasectomy or surgical castration ≥ 6 months prior to Screening. 12. Able to swallow study medication 13. Able to comply with study requirements

Exclusion Criteria

  1. Received any investigational agent within 5 half-lives of the agent in question; if the half-life is not known, ≤ 28 days of C1D1.
  2. Received palliative radiotherapy ≤ 2 weeks of C1D1
  3. Received any other therapeutic treatment for breast cancer ≤ 2 weeks of C1D1, except for hormonal therapies.
  4. Symptomatic CNS metastases.
  5. History of another invasive malignancy ≤ 3 years of C1D1.
  6. A QTcF interval >470 msec on the Screening ECG. If the ECG QTcF interval is >470 msec, then the mean QTcF of a triplicate ECGs can be used and if the mean is <470 msec, the subject may be enrolled.
  7. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, atrial fibrillation with rapid ventricular response, torsades de pointes, second degree or third degree atrioventricular heart block without a permanent pacemaker in place).
  8. Class III or IV Congestive Heart Failure (CHF) as defined by the New York Heart Association (NYHA) functional classification system within the previous 6 months
  9. Initiated a bone modifying agent (e.g. denosumab) ≤ 28 days of C1D1.
  10. Any medical condition that could preclude their participation in the study, pose an undue medical hazard, or which could interfere with the interpretation of the study results.
  11. A history of seizure ≤ 2 years of C1D1 or those who require prophylactic anti-seizure medications.
  12. A history of loss of consciousness or transient ischemic attack ≤ 12 months before C1D1.
  13. Known active HIV, Hepatitis B, or Hepatitis C infections.
  14. Known or suspected hypersensitivity to seviteronel, or any components of the formulation.
  15. Any other condition which in the opinion of the investigator would preclude participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02580448

  Hide Study Locations
Layout table for location information
United States, Alabama
Wallace Tumor Institute- University of Alabama
Birmingham, Alabama, United States, 35249
Clearview Cancer Institute
Huntsville, Alabama, United States, 35805
United States, Colorado
University of Colorado
Aurora, Colorado, United States, 80045
Rocky Mountain Cancer Centers
Lakewood, Colorado, United States, 80228
United States, Florida
Florida Cancer Specialists
Fort Myers, Florida, United States, 33916
Florida Cancer Specialists- North
Saint Petersburg, Florida, United States, 33705
United States, Georgia
Georgia Cancer Center at Augusta University
Augusta, Georgia, United States, 30912
United States, Kansas
SCRI - HCA Midwest Division
Kansas City, Kansas, United States, 61432
United States, Kentucky
University of Louisville Hospital / James Brown Cancer Center
Louisville, Kentucky, United States, 40202
United States, Maryland
Maryland Oncology Hematology
Silver Spring, Maryland, United States, 20902
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
Henry Ford Hospital
Detroit, Michigan, United States, 48202
United States, Minnesota
Masonic Cancer Center
Minneapolis, Minnesota, United States, 55455
United States, Nebraska
Cancer Network/Oncology Associates PC
Omaha, Nebraska, United States, 68118
Nebraska Cancer Specialists
Omaha, Nebraska, United States, 68130
United States, New Jersey
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
United States, New York
North Shore Hematology Oncology Associates
East Setauket, New York, United States, 11733
Memorial Sloan Kettering
New York, New York, United States, 10065
United States, North Carolina
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States, 27599
Novant Health Presbyterian Medical Center - Oncology Research
Charlotte, North Carolina, United States, 28204
Duke University
Durham, North Carolina, United States, 27710
United States, Ohio
Gabrail Cancer Center Research
Canton, Ohio, United States, 44718
Oncology Hematology Care, Inc
Cincinnati, Ohio, United States, 45242
The Ohio State University
Columbus, Ohio, United States, 43202
United States, Oklahoma
Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73104
United States, Oregon
OHSU Knight Cancer Institute
Portland, Oregon, United States, 97239
United States, South Carolina
Charleston Hematology and Oncology Associates
Charleston, South Carolina, United States, 29414
United States, Tennessee
Precision Cancer Research/Brig Center for Cancer Care and Survivorship, LLC
Knoxville, Tennessee, United States, 37909
SCRI Tenessee Oncology Nashville
Nashville, Tennessee, United States, 37203
United States, Texas
Mary Crowley Cancer Research Centers
Dallas, Texas, United States, 75230
The University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390
The Center for Cancer and Blood Disorders (Fort Worth)
Fort Worth, Texas, United States, 76104
US Oncology
Fort Worth, Texas, United States, 76177
United States, Utah
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
United States, Virginia
Virginia Oncology Associates
Norfolk, Virginia, United States, 23502
Sponsors and Collaborators
Innocrin Pharmaceutical
Layout table for investigator information
Study Chair: Victoria Brown, BS Sponsor GmbH

Layout table for additonal information
Responsible Party: Innocrin Pharmaceutical Identifier: NCT02580448     History of Changes
Other Study ID Numbers: INO-VT-464-CL-006
First Posted: October 20, 2015    Key Record Dates
Last Update Posted: February 1, 2019
Last Verified: January 2019
Keywords provided by Innocrin Pharmaceutical:
Breast Cancer
Advanced Breast Cancer
Metastatic Breast Cancer
Male Breast Cancer
Triple Negative Cancer
ER+ Breast Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Triple Negative Breast Neoplasms
Breast Neoplasms, Male
Neoplasms by Site
Breast Diseases
Skin Diseases